Mobil bleiben und produzieren, ohne die natürliche Regenerationsfähigkeit der Erde zu überfordern, das ist der Anspruch des InnovationsCampus Mobilität der Zukunft (ICM) am Karlsruher Institut für Technologie und der Universität Stuttgart. Fast 300 Forschende in gut 60 Forschungsprojekten und 40 -instituten arbeiten hier an Elektromotoren ohne Seltene Erden, neuartigen Fertigungstechnologien und selbstlernenden Software-Systemen für Fahrzeuge.

Population growth and the increasing standard of living make our society face big ecological challenges: Climate change, littering of the seas, dwindling agricultural areas, resource scarcity. Bioeconomy aims at replacing fossil by regenerative resources and at using advanced and sustainable technologies based on biological knowledge and principles.

University of Hohenheim project contributes to maintaining valuable biotopes: Autonomous robot to help prune fruit trees so they stay healthy.

Refuels are renewable fuels that can be produced in different ways. When they are mixed and processed such that they meet the existing fuel standards, they are suited for all types of combustion engines. This is the result of the latest vehicle and fleet tests within the project “reFuels – Rethinking Fuels” at Karlsruhe Institute of Technology (KIT). Compared to fully fossil fuels, refuel mixes allow for a CO2 reduction by 25% at least. Moreover,…

Dossier - 02/12/2013

RNA interference confidence is returning

The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

Dossier - 05/08/2013

Progress expands bioethical boundaries

Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. Rapid progress in genetic engineering and cell biology means that it is necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be carried out.

Dossier - 12/03/2012

Regenerative medicine makes use of patients own resources

Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.

Article - 08/07/2021

Individual operation risk assessment by the Cognitive Medical Assistant

Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…

Dossier - 31/03/2014

Peptides diverse molecules of life

Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Peptides are gaining in importance as candidates for drugs.

Alpha-Protein GmbH - 27/07/2021

Insect farming for sustainability

Mealworms instead of fish meal and soybean meal - this is what the sustainable future of feed production looks like as Alpha-Protein GmbH see it. The company has built a highly efficient automated production plant in which residual materials from local food production are used to breed mealworms.

Dossier - 21/05/2013

No new drugs to be placed on the market without clinical trials

New pharmaceuticals are subject to approval by drug authorities. Here clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the drug. The costs including failures can amount to approximately one billion US dollars per drug.

Dossier - 01/10/2012

Systems biology understanding complex biological systems

Systems biology studies complex interactions within biological systems on the genome proteome and organelle level. Many techniques from the fields of systems theory and associated fields can be used to gain an understanding of the behaviour and biological mechanisms of cellular systems.

Dossier - 01/10/2012

Systems biology understanding complex biological systems

Systems biology studies complex interactions within biological systems on the genome proteome and organelle level. Many techniques from the fields of systems theory and associated fields can be used to gain an understanding of the behaviour and biological mechanisms of cellular systems.

Zero Bullshit Company - 31/05/2021

From being thrown away to becoming a recycled product - Stuttgart start-up produces healthy snacks

Throwing away food? The Stuttgart-based start-up Zero Bullshit Company is declaring war on food wastage by making nutrient-rich products largely from food industry leftovers. The three food technologists who created this transparent brand are looking to develop more than just delicious and nutritious products.

Dossier - 18/06/2012

Biobanks treasure chests for biomedical research

The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a biobanking law during the current mandate.